生物技术公司Arrowhead和Sarepta达成了一项价值5亿美元的交易, Biotech firms Arrowhead and Sarepta form a $500M+ deal targeting rare genetic diseases.

箭头制药公司和Sarepta治疗机构开展了重要的合作,重点是影响肌肉、中枢神经系统和肺部的罕见遗传疾病。 Arrowhead Pharmaceuticals and Sarepta Therapeutics have entered a significant collaboration focused on rare genetic diseases affecting muscles, the central nervous system, and lungs. 根据协议，Sarepta 向 Arrowhead 支付 5 亿美元的预付款，并投资 3.25 亿美元的股权，潜在的特许权使用费和里程碑付款高达 100 亿美元。 Under the agreement, Sarepta pays Arrowhead $500 million upfront and invests $325 million in equity, with potential royalties and milestone payments up to $10 billion. 该协议包括4种临床阶段药物,允许萨雷普塔在五年内提出最多6个新的研究目标。 The deal includes four clinical-stage drugs and allows Sarepta to propose up to six new research targets over five years. 箭头的股票在新闻上猛增。 Arrowhead's stock surged on the news.